Targeted drugs are mainly used to treat patients with inoperable advanced kidney cancer or patients with postoperative recurrence and metastasis, which usually have poor prognosis, and a study said that the median progression-free survival of Sunitinib-treated patients with advanced kidney cancer is 11.3 months. Kidney cancer is a common malignant tumor of the urinary system. Localized renal cancer can be treated by surgery, but metastatic renal cancer and advanced renal cancer are not sensitive to traditional radiotherapy, and targeted drugs are one of the main means of treating advanced renal cancer, such as sorafenib, sunitinib, tesiromide, bevacizumab, everolimus, pezopanib, as well as acitretinib and levatinib. Targeted drugs are mainly used for the treatment of inoperable advanced renal cancer, adjuvant treatment of advanced renal cancer after undergoing palliative surgery or tumor reduction surgery, neoadjuvant treatment of advanced or progressed renal cancer before surgery, or patients with recurrent progression after surgery. A study in China says that the median progression-free survival of Sunitinib treatment for patients with advanced kidney cancer is 11.3 months. It is recommended to go to regular hospitals for comprehensive assessment of the condition, follow the doctor’s instructions to cooperate with the treatment, choose the appropriate treatment plan to improve the prognosis of the patients, so as to avoid delaying the condition. Please strictly follow the doctor’s instructions for drug treatment and do not use drugs by yourself.